These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 16498486)
1. PHARMAC's response on clopidogrel. Moodie P; Dougherty S N Z Med J; 2006 Feb; 119(1229):U1872. PubMed ID: 16498486 [No Abstract] [Full Text] [Related]
2. PHARMAC and lack of funding for clopidogrel. White H; Ellis C N Z Med J; 2005 Jan; 119(1228):U1808. PubMed ID: 16462916 [TBL] [Abstract][Full Text] [Related]
3. [Scope of the contract for drug therapy. Rebate contracts also for original drugs]. MMW Fortschr Med; 2009 Jul; 151(30-33):80. PubMed ID: 19722473 [No Abstract] [Full Text] [Related]
4. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. Akinlade BK N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12571267 [No Abstract] [Full Text] [Related]
5. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. Ramsey SD N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572583 [No Abstract] [Full Text] [Related]
6. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. Yaes RJ N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572584 [No Abstract] [Full Text] [Related]
7. Clopidogrel in acute coronary syndromes: can the cost effectiveness improve? Sánchez-Delgado E Circulation; 2003 Aug; 108(8):e56; author reply e56. PubMed ID: 12939246 [No Abstract] [Full Text] [Related]
8. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. Armstrong EC N Engl J Med; 2003 Feb; 348(6):560-3; author reply 560-3. PubMed ID: 12572582 [No Abstract] [Full Text] [Related]
9. [After coronary intervention. Which platelet inhibitor for whom?]. Stiefelhagen P MMW Fortschr Med; 2007 Apr; 149(14):18-9. PubMed ID: 17668756 [No Abstract] [Full Text] [Related]
10. [Clopidogrel--an expensive thrombocyte inhibitor with a small marginal benefit]. Asplund K Lakartidningen; 2000 Mar; 97(11):1294-6. PubMed ID: 10771550 [No Abstract] [Full Text] [Related]
11. PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric. Grocott R; Metcalfe S N Z Med J; 2012 Jul; 125(1358):89-90. PubMed ID: 22864151 [No Abstract] [Full Text] [Related]
12. Clopidogrel and long-term outcomes after drug-eluting stent implantation. Falcone EL; Tangri N JAMA; 2007 Apr; 297(16):1770; author reply 1770-1. PubMed ID: 17456815 [No Abstract] [Full Text] [Related]
13. Antifibrinolytics may be cost saving among recent recipients of combined acetylsalicylic acid and clopidogrel who undergo coronary artery bypass graft surgery. Ray JG; Hamielec CM Can J Cardiol; 2004 Jun; 20(8):829-30. PubMed ID: 15229768 [No Abstract] [Full Text] [Related]
14. Clopidogrel(TM): an alternative to acetylsalicylic acid and ticlopidine in antiplatelet therapy? Shukla V Issues Emerg Health Technol; 1999 Jan; (6):1-4. PubMed ID: 11811213 [No Abstract] [Full Text] [Related]